GlobeNewswire

Invitation to the special and extraordinary shareholders' meetings

Share

Mechelen, Belgium; 20 September 2019, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) invites its shareholders to a special and extraordinary shareholders' meeting.

On 14 July 2019, Galapagos NV (the "Company" or "Galapagos") announced that it entered into a collaboration with Gilead Sciences, Inc., Gilead Biopharmaceutics Ireland UC, and Gilead Therapeutics A1 Unlimited Company. In view hereof, Galapagos has the honor to invite its shareholders, warrant holders, directors, and statutory auditor to its special and extraordinary shareholders' meetings that will be held on Tuesday 22 October 2019 at 2:00 p.m. (CEST) at the Company's registered office.

The items on the agenda of the special and extraordinary general meetings of shareholders include, amongst other things, the appointment of Mr. Daniel O'Day and Dr. Linda Higgins as directors of the Company, the approval of the issuance of two warrants for the benefit of Gilead Therapeutics A1 Unlimited Company, and the renewal of the Company's authorized capital by up to 20% of the share capital.

In order to be admitted to the shareholders' meetings, the holders of securities issued by the Company must comply with article 536 of the Belgian Companies Code of 7 May 1999 and article 29 of the Company's articles of association, and fulfill the formalities described in the convening notice. The convening notice and other documents pertaining to the shareholders' meetings, including the biographies of Mr. O’Day and Dr. Higgins, can be consulted on our website (www.glpg.com ).

About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.

  
Contact

Investors: Media:
Elizabeth Goodwin  Carmen Vroonen
VP IR  Senior Director Communications
+1 781 460 1784  +32 473 824 874
   
Sofie Van Gijsel   Evelyn Fox
Director IR  Director Communications
+32 485 19 14 15  +31 6 53 591 999
ir@glpg.com  communications@glpg.com

Forward-looking statements
This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.

Disclaimer
The contents of our website, including the special reports prepared by the board of directors and the statutory auditor at the occasion of the shareholders' meetings of 22 October 2019, and any other website that may be accessed from our website, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

ENR Russia Invest SA announces a new private equity investment and end third quarter 2019 net asset value per share23.10.2019 19:15:00 CESTPress release

Press Release Geneva, 23 October 2019 ENR RUSSIA INVEST SA ANNOUNCES A NEW PRIVATE EQUITY INVESTMENT AND END THIRD QUARTER 2019 NET ASSET VALUE PER SHARE New private equity investment ENR Russia Invest SA, via a wholly owned subsidiary (“ENR”), acquired a 50% interest in a 27.4 hectare greenhouse and engineering facility for flower growing in the Kaluga Oblast in Russia (“Flower Growing Facility”). ENR teamed-up with a Russia based investment group, who owns the remaining 50% interest (collectively referred to as the “Investors”). The purchase price and initial investment for capital and operational expenses is RUB 742 million (approximately CHF 11.5 million). ENR’s 50% contribution is RUB 371 million (approximately CHF 5.75 million). Together with further investments (see below), it is anticipated that the Investors could ultimately invest a total of about CHF 20 million (or less if low interest rate Russian bank funding can be obtained under Russian agricultural incentive programs).

Press Release: Giuseppe Pasceri appointed as General Manager for Adevinta in Italy23.10.2019 17:00:00 CESTPress release

Italy, 23 october 2019: Adevinta, a global online classifieds company with generalist, real estate, cars, jobs and other internet marketplaces in 16 countries, today announces that Giuseppe Pasceri will succeed Melany Libraro as the new General Manager for Adevinta in Italy, overseeing Subito and InfoJobs. Giuseppe joined Adevinta Italy in 2018 from the Italian Government Digital Team, bringing extensive experience in digital transformation and user-centered businesses. He most recently served as Chief Product Officer and Chief Technology Officer for Adevinta Italy. Giuseppe has over 25 years of experience in digital businesses, having worked for companies such as Yahoo!, eBay, RCS, Jobrapido and the Italian Government Digital Service. In his new role, Giuseppe will oversee all aspects of Subito and InfoJobs’ strategy and execution, with the goal to increase Adevinta’s leadership position in Italy and improve our users experience. “Giuseppe brings a thorough understanding of our users

Articles of Association, Seluxit A/S23.10.2019 15:32:00 CESTPress release

Articles of Association, Seluxit A/S Company Announcement No. 15 Aalborg, 23. October 2019 Articles of Association, Seluxit A/S. Following the completion of the registration with the Danish Commerce and Companies Agency (Erhvervsstyrelsen), attached you find the updated articles of association containing the changes which were decided at Seluxit A / S 'annual general meeting on October 22, 2019 For further information, please contact CEO Daniel Lux. You can subscribe to our investor newsletter on https://www.seluxit.com/investors and get company announcements directly in your mail box. You can also follow news from Seluxit on Homepage: https://www.seluxit.com/blog LinkedIn: https://www.linkedin.com/company/seluxit Facebook: https://www.facebook.com/seluxit Seluxit A/S Hjulmagervej 32B 9000 Aalborg Denmark Tel.: +45 46 922 722 E-mail: investor@seluxit.com Web: www.seluxit.com CVR/VAT nr. 29388237 Certified Adviser Norden CEF ApS, V/ John Norden Kongevejen 365, 2840 Holte Denmark Tel.: +

Aker and REV Ocean Pledge USD 11 million to Technology Initiatives for a Healthy Ocean23.10.2019 15:15:00 CESTPress release

Oslo, 23 October 2019 – The Aker Group, REV Ocean and The Resource Group (TRG) today announced a joint pledge of USD 11 million to three initiatives dedicated to developing disruptive technology solutions for a healthy and productive ocean. “Throughout its 180-year history, the Aker group has been a driving force in the development of knowledge-based industry related to ocean resources. All our industrial activities are part of the ocean economy,” said Aker President and CEO Øyvind Eriksen. “Today, our ocean is at risk and changes are needed. I strongly believe that solutions for the ocean are developed more robustly and swiftly if businesses like Aker join forces with governments, NGOs and other stakeholders. A healthier ocean is a shared interest,” he said. The USD 11 million pledge will go towards three initiatives, covering costs for the next three years. The initiatives include the Centre for the Fourth Industrial Revolution (C4IR) in Norway, which will receive USD 6 million, the

AB Klaipėdos nafta (KN) will hold an Investor Conference Webinar to introduce unaudited financial results for the nine months of 201923.10.2019 14:33:00 CESTPress release

KN invites shareholders, investors, analysts and other stakeholders to join its investor conference webinar scheduled on the October 30th of 2019 at 8.30 am (EET). The presentation will be held in English. The webinar will be hosted by Company’s management who will introduce the performance and unaudited financial results of KN for the nine months of 2019. After the presentation investors are welcome to ask questions. Due to limited webinar time, we encourage participants to send their questions before the webinar until October 28th to Justinas.Juknys@nasdaq.com How to join the webinar? To join the webinar, please register via following link: https://attendee.gotowebinar.com/register/2162981666275406850 You will be provided with the webinar link and instructions how to join successfully. When joining the webinar for the first time, you will be asked to download the plug-in which will take only few seconds. In case plug-in can't be downloaded, a web browser which enables attending the w

ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-4323.10.2019 13:30:00 CESTPress release

Results follow recent updates to ProMIS antibody programs selectively targeting root cause of multiple neurodegenerative diseases TORONTO and CAMBRIDGE, Mass., Oct. 23, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has generated antibody candidates targeting the neurotoxic form of TAR DNA-binding protein 43 (TDP-43), a protein found in all cells and implicated as a root cause in a spectrum of diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). New data generated by ProMIS’ unique drug discovery and development platform demonstrate that several antibody candidates show selectivity for toxic, misfolded intracellular aggregates of TDP-43 with no binding to normal TDP-43 located in the cell nucleus. ProMIS antibody candidates also show selective bi